Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO ₂ as the primary endpoint – – STRATUS-HCM on track to start in the fourth quarter of 2026 – BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today...